Lifestyle intervention for type 2 diabetes risk reduction: Using the diabetes prevention program to inform new directions in pediatric research

Canadian Journal of Diabetes

Volumn 31, Issue 3, 2007, Pages 242-251

  Franks, Paul W ^a   Huang, Terry T K ^b   Ball, Geoff D C ^c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adolescent; Child; Pediatric; Prevention; Randomized clinical trial; Youth

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; TROGLITAZONE;

ABDOMINAL SUBCUTANEOUS FAT; ANTHROPOMETRIC PARAMETERS; BLOOD CLOTTING; BLOOD PRESSURE; BODY FAT DISTRIBUTION; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC DIET; DIABETIC OBESITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEALTH HAZARD; HEALTH PROGRAM; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID METABOLISM; MEDICAL RESEARCH; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PEDIATRICS; PHYSICAL ACTIVITY; PREVALENCE; PREVENTIVE MEDICINE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SKINFOLD THICKNESS; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

EID: 34948910217     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(07)13011-2     Document Type: Article

References (54)

1. Dean HJ, Young TK, Flett B, et al. Screening for type 2 diabetes in aboriginal children in northern Canada. Lancet. 1998;7:1523-1524.
2. Harris SB, Perkins BA, Whalen-Brough E. Non-insulin-dependent diabetes mellitus among First Nations children. New entity among First Nations people of north western Ontario. Can Fam Physician. 1996;42:869-876.
3. Liese AD, D'Agostino RB Jr., Hamman RF, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the Search for Diabetes in Youth Study. Pediatrics. 2006;118:1510-1518.
4. Weiss R, Taksali SE, Tamborlane WV, et al. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005;28:902-909.
5. Goran MI, Bergman RN, Avila Q, et al. Impaired glucose tolerance and reduced beta-cell function in overweight Latino children with a positive family history for type 2 diabetes. J Clin Endocrinol Metab. 2004;89:207-212.
6. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 2002;346:802-810.
7. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2003;27:S1-S152.
8. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
9. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
10. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-297.
11. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
12. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374-1383.
13. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: recruitment methods and results. Control Clin Trials. 2002;23:157-171.
14. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
15. The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring). 2006;14:2107-2117.
16. Carnethon MR, Prineas RJ, Temprosa M, et al. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006;29:914-919.
17. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241-250.
18. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007;56:531-536.
19. Florez JC, Jablonski KA, Sun MW, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007;92:1502-1509.
20. Fujimoto WY, Jablonski KA, Bray GA, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56:1680-1685.
21. Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566-1572.
22. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102-2107.
23. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404-2414.
24. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-619.
25. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care. 2005;28:888-894.
26. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care. 2000;23:1619-1629.
27. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22:623-634.
28. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273:402-407.
29. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-384.
30. Uusitupa M, Lindi V, Louheranta A, et al. Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52:2532-2538.
31. Hamalainen H, Ronnemaa T, Virtanen A, et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia. 2005;48:2248-2253.
32. Herder C, Peltonen M, Koenig W, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes. 2006;55:2340-2346.
33. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
34. Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care. 2004;27:2135-2140.
35. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotype-phenotype associations. Nature. 2007;447:655-660.
36. Grarup N, Andersen G. Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism. Curr Opin Clin Nutr Metab Care. 2007;10:420-426.
37. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-323.
38. Cauchi S, El Achhab Y, Choquet H, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med. 2007;85:777-782.
39. Yates T, Khunti K, Bull F, et al. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia. 2007;50:1116-1126.
40. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334:299.
41. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075-1081.
42. Huang TT, Goran MI. Prevention of type 2 diabetes in young people: a theoretical perspective. Pediatr Diabetes. 2003;4:38-56.
43. Ball GD, Huang TT, Gower BA, et al. Longitudinal changes in insulin sensitivity, insulin secretion, and beta-cell function during puberty. J Pediatr. 2006;148:16-22.
44. Meyer AA, Kundt G, Lenschow U, et al. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. J Am Coll Cardiol. 2006;48:1865-1870.
45. Ribeiro MM, Silva AG, Santos NS, et al. Diet and exercise training restore blood pressure and vasodilatory responses during physiological maneuvers in obese children. Circulation. 2005;111:1915-1923.
46. Shaibi GQ, Cruz ML, Ball GD, et al. Effects of resistance training on insulin sensitivity in overweight Latino adolescent males. Med Sci Sports Exerc. 2006;38:1208-1215.
47. Woo KS, Chook P, Yu CW, et al. Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation. 2004;109:1981-1986.
48. Baranowski T, Cooper DM, Harrell J, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care. 2006;29:212-217.
49. Centers for Disease Control and Prevention. 2000 CDC Growth Charts:United States. Washington, DC: Department of Health and Human Services, National Center for Health Statistics; 2000. Available at: http://www.cdc.gov/growthcharts/. Accessed August 15, 2007.
50. Zeitler P, Epstein L, Grey M, et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74-87.
51. Dabelea D, D'Agostino RB Jr., Mayer-Davis EJ, et al. Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care. 2006;29:290-294.
52. Mayer-Davis EJ, Nichols M, Liese AD, et al. Dietary intake among youth with diabetes: the SEARCH for Diabetes in Youth Study. J Am Diet Assoc. 2006;106:689-697.
53. Petitti DB, Imperatore G, Palla SL, et al. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch Pediatr Adolesc Med. 2007;161:159-165.
54. Dabelea D, Bell RA, D'Agostino RB Jr., et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-2724.